Tag: Prasugrel

1. Guided selection of antiplatelet therapy reduced rates of major adverse cardiovascular event rates compared to standard therapy. 2. Guided selection strategy was beneficial for both escalation and de-escalation of standard therapy, balancing patient-dependent ischemic and bleeding risks.  Evidence Rating Level: 1 (Excellent) Study Rundown: Patients who undergo percutaneous coronary intervention (PCI)...
1. There does not appear to be any difference in outcome between pre- and post-treatment administration of P2Y12 inhibitors among patients experiencing a non-ST elevation acute coronary syndrome with planned invasive intervention. 2. Prasugrel and ticagrelor showed similar outcomes when administered post-treatment. Evidence Rating Level: 1 (Excellent) Though it is well established...
1. In this modern population of Canadian patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI), the rates of major adverse cardiovascular events (MACE) at 1 year follow-up were the same in groups treated with ticagrelor or clopidogrel. Ticagrelor was linked with a higher risk of...
Image: PD 1. Prasugrel was more effective than clopidogrel in reducing the incidence of recurrent myocardial infarction in patients presenting with acute coronary syndrome, though there was no difference in mortality between the two groups 2. Patients treated with prasugrel had a significantly higher incidence of fatal major bleeding compared to...